← FDA DRUG APPROVALS

FDA ANDA · ANDA206827

CELECOXIB

Sponsor: AUROBINDO PHARMA

APPLICATION
ANDA206827
TYPE
ANDA
ORIGINAL APPROVAL
2016-02-01
LATEST ACTION
2024-12-19
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

CELECOXIBPrescription
CELECOXIB 400MG · CAPSULE · ORAL
CELECOXIBPrescription
CELECOXIB 100MG · CAPSULE · ORAL
CELECOXIBPrescription
CELECOXIB 200MG · CAPSULE · ORAL
CELECOXIBPrescription
CELECOXIB 50MG · CAPSULE · ORAL

Approval history

2024-12-19Labeling · Supplement 13 · standardAP
2022-01-05Labeling · Supplement 9 · standardAP
2019-09-09Labeling · Supplement 6 · standardAP
2019-07-25Labeling · Supplement 4 · standardAP
2016-09-14Labeling · Supplement 2 · standardAP
2016-02-01UNKNOWN · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →